Recent Updates
Recently added Catalysts

GE-287

Phase 2

Cognitive Dysfunction | Small molecule | Neurology |GE HealthCare Technologies Inc.|Trials Updated: Oct 14, 2026

GE-287 development status

Highest phase Phase 2
Registered trials 1 across 1 sponsor since Oct 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials1
Total Enrollment20

FDA Designations

No designations recorded

GE-287 clinical trials

GE-287 · 1 trial · 1 indication

Phase 2 1
NCT07873463Flutemetamol F 18 Injection Formulation ComparisonCognitive Dysfunction
NOT YET_RECRUITING20 Analytics
PHASE2NOT YET_RECRUITING
Flutemetamol F 18 Injection Formulation Comparison
Cognitive Dysfunction
NCT0787346320
Unlock trial analytics

Study Endpoints

Primary Endpoints

Comparison of Standard Uptake Value ratio in frontal and anterior cingulate brain region
90-100 minutes after product administration
Comparison of SUVr in posterior cingulate and precuneus brain region
90-100 minutes after product administration
Comparison of SUVr in lateral temporal brain region
90-100 minutes after product administration
Comparison of SUVr in inferolateral parietal brain region
90-100 minutes after product administration
Comparison of Standard Uptake Value (SUV) in heart
0-60 minutes after product administration
Comparison of SUV in liver
0-60 minutes after product administration
Comparison of SUV in kidneys
0-60 minutes after product administration

Secondary Endpoints

Comparison of global brain Centiloid values
90-100 minutes after product administration
Comparison of SUV in heart
105-150 minutes after product administration
Comparison of SUV in liver
105-150 minutes after product administration
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingSINGLE
ModelCROSSOVER
PurposeDIAGNOSTIC

Treatment Arms

ArmTypeDescription
GE-287 then VizamylOTHER -
VIZAMYL then GE-287OTHER -

Interventions

NameTypeDescription
GE-287DRUGDrug: GE-287 185 MBq (±10%) of GE-287 administered intravenously
VizamylDRUGDrug: Vizamyl 185 MBq (±10%) of Vizamyl administered intravenously
Unlock Study Design Details

Eligibility Criteria

Age Range50 Years to 110 Years
SexALL
Healthy VolunteersNo
Study Sites6

Inclusion Criteria: * The participant is at least 50 years of age * The participant (or a legally authorized representative of the participant) has read, signed, and dated an informed consent form (ICF) before any study procedures are performed. * The participant has been referred for PET imaging w...

Countries:United States
Unlock Eligibility Criteria

Explore more on BiopharmaWatch

GE HealthCare Technologies Inc. (GEHC)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with GCompanies A to ZEvery biotech and pharma company we track